Filing Flows

Filing Flows › Companies › Stemtech › Cash flow

Stemtech cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$55K in Q2 2026 · −$329K over twelve months

Operating cash flow−$55K
Free cash flow−$55K
Cash conversion cycle-3066 days

Analysis

In Q2 2026, Stemtech generated −$55K of operating cash flow. That is $130K less than in Q2 2025 ($75K).

Over the twelve months to Jun 30, 2026, operating cash flow was −$329K; the largest uses were operating cash flow ($329K); besides operations, cash came from other financing ($85K); the cash balance fell by $26K.

Operating cash flow was −$55K against net income of −$292K. The largest differences: deferred revenue −$332K, payables +$174K, stock-based pay +$109K.

Its cash conversion cycle was -3066 days (receivables 1 + inventory 177 − payables 3244): suppliers fund its working capital.

Free cash flow

Stemtech: free cash flow by quarterStemtech: free cash flow by quarter−$1.2MQ3 2024−$271KQ4 2024−$711KQ1 2025$75KQ2 2025$25KQ3 2025$127KQ4 2025−$426KQ1 2026−$55KQ2 2026
Operating cash flow less capital spending.
Stemtech: operating cash flow against capital spendingStemtech: operating cash flow against capital spendingOperating cash flowCapital spending−$1.2M$0Q3 2024−$271K$0Q4 2024−$711K$0Q1 2025$75K$0Q2 2025$25K$0Q3 2025$127K$0Q4 2025−$426K$0Q1 2026−$55K$0Q2 2026
Latest (Q2 2026): Operating cash flow −$55K, Capital spending $0.

Capital allocation, year by year

Stemtech: where the cash came from (up) and went (down), by fiscal yearStemtech: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedFY2021: Operating cash flow −$1.9MFY2021: Net borrowing $2.6M$2.6MFY2021FY2022: Operating cash flow −$1.2MFY2022: Net borrowing $24KFY2022: Shares issued $100K$124KFY2022FY2023: Operating cash flow −$2.0MFY2023: Net borrowing $1.8M$1.8MFY2023FY2024: Operating cash flow −$601KFY2024: Net borrowing $275KFY2024: Shares issued $475K$750KFY2024FY2025: Operating cash flow −$484KFY2025: Net borrowing $291K$291KFY2025
Over these 5 years operating cash flow totalled −$6.3M; the largest uses were operating cash flow ($6.3M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$247K
Debt$4.4M
Net debt$4.1M
Cash runway9 months

Stemtech is burning cash: its operations consume cash, a free cash flow of −$329K a year at the current rate against $247K of cash and investments: a runway of about 9 months before any new financing.

Where the cash came from and went

Stemtech: sources (+) and uses (−) of cash, Q2 2026Stemtech: sources (+) and uses (−) of cash, Q2 2026Other financing$200KExchange rates−$155KOperating cash flow−$55KCash drawn (+) / kept (−)$9K
Stemtech: sources (+) and uses (−) of cash, TTM to Q2 2026Stemtech: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$329KExchange rates$218KOther financing$85KCash drawn (+) / kept (−)$26K

From profit to cash

Stemtech: net income to operating cash flow, Q2 2026Stemtech: net income to operating cash flow, Q2 2026Net income−$292KDepreciation & amortization$42KStock-based pay$109KInventory$14KPayables$174KDeferred revenue−$332KPrepaid and other assets−$2KOperating cash flow−$55K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 202611773244-3066
Q1 202612244593-4369
Q4 2025332014782-4548
Q3 2025361382863-2689
Q2 2025401443152-2968
Q1 2025271172781-2636

Every quarter

QuarterOperating cash flowNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$55K——$9K−$55K
Q1 2026−$426K——−$18K−$426K
Q4 2025$127K−$25K—$17K$127K
Q3 2025$25K−$163K—$17K$25K
Q2 2025$75K$2K—$33K$75K
Q1 2025−$711K$367K—−$51K−$711K
Q4 2024−$271K$13K$475K−$1.2M−$271K
Q3 2024−$1.2M——$1.2M−$1.2M

Stemtech: income statement and cash flow

Stemtech, Q2 2026: revenue $629K (-10% year over year), operating margin -20.0%. The chart follows the revenue to costs, profit and cash.

Stemtech: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.